Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital decreased their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Stock Up 3.1 %

NASDAQ:EVGN opened at $1.67 on Tuesday. The company has a market cap of $8.96 million, a P/E ratio of -0.37 and a beta of 1.43. Evogene has a twelve month low of $1.44 and a twelve month high of $10.40. The business has a 50 day moving average price of $2.37 and a two-hundred day moving average price of $4.40.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.